Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
Authors
Hiroo Ishida
Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan;
Hiroo Ishida , Yu Sunakawa , Yasuhiro Kodera , Kazuhiro Yoshida , Mitsugu Kochi , Yoshihiro Kakeji , Takeshi Sano , Wataru Ichikawa , Masashi Fujii , Masahiro Takeuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000010337
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 371)
DOI
10.1200/JCO.2023.41.4_suppl.371
Abstract #
371
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2017 ASCO Annual Meeting
Phase III study of individualized intraperitoneal/intravenous/oral chemotherapy compared with standard intravenous/oral chemotherapy in patients with advanced gastric cancer.
First Author: Yang Yang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2017 Gastrointestinal Cancers Symposium
Trastuzumab beyond progression in patients with HER2 positive advanced gastric adenocarcinoma: A multicenter AGEO study.
First Author: Juliette Palle